This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Theratechnologies (THTX) Gets a Hold from JonesTrading

Tipranks - Tipranks - Fri Jul 11, 2025

JonesTrading analyst Justin Walsh reiterated a Hold rating on Theratechnologies today. The company’s shares closed yesterday at $3.14.

Don’t Miss TipRanks’ Half-Year Sale

Walsh covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Y-Mabs Therapeutics, and Achieve Life Sciences. According to TipRanks, Walsh has an average return of -3.6% and a 30.95% success rate on recommended stocks.

Currently, the analyst consensus on Theratechnologies is a Hold with an average price target of $2.56.

See Insiders’ Hot Stocks on TipRanks >>

Based on Theratechnologies’ latest earnings release for the quarter ending February 28, the company reported a quarterly revenue of $19.05 million and a net profit of $117 thousand. In comparison, last year the company earned a revenue of $16.25 million and had a GAAP net loss of $4.48 million

Read More on THTX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).